Fixed dose combination (antiretroviral)
Jump to navigation
Jump to search
Fixed dose combinations of antiretrovirals are multiple antiretroviral drugs combined into a single pill, which helps reduce pill burden. They may combine different classes of antiretrovirals or contain only a single class. Licensed fixed dose combinations are shown in the table below.
| Brand Name | Drug Names (INN) | Date of FDA Approval | Company |
|---|---|---|---|
| Combivir® | zidovudine + lamivudine | September 26, 1997 | GlaxoSmithKline |
| Trizivir® | abacavir + zidovudine + lamivudine | November 15, 2000 | GlaxoSmithKline |
| Kaletra® | lopinavir + ritonavir | September 15, 2000 | Abbott Laboratories |
| Epzicom® (in USA) Kivexa® (in Europe) |
abacavir + lamivudine | August 2, 2004 | GlaxoSmithKline |
| Truvada® | emtricitabine + tenofovir | August 2, 2004 | Gilead Sciences |
| Atripla® | efavirenz + emtricitabine + tenofovir | July 12, 2006 | Gilead Sciences and Bristol-Myers Squibb |